September 5, 2024
Clonal hematopoiesis of indeterminate potential (CHIP) and mosaic chromosomal alterations (mCAs) are associated with an increased risk for breast cancer, and CHIP is associated with increased […]
September 5, 2024
After 8 years of service, Dana-Farber Cancer Institute president and CEO Laurie Glimcher, MD, will step down from her post on October 1, according to a […]
September 5, 2024
TOPLINE: In patients with prostate cancer, androgen receptor pathway inhibitors (ARPIs) extended the median time to no longer clinically benefitting (NLCB) to 11.1 months vs the […]
September 4, 2024
TOPLINE: Patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) treated with immune checkpoint inhibitors (ICIs) show comparable survival outcomes whether they continued […]
September 4, 2024
TOPLINE: Nearly 45% of cancer survivors face financial hardship during and after their cancer care, with factors including higher social vulnerability, younger age, lower income, and […]
September 3, 2024
LONDON (Reuters) -There is no link between mobile phone use and an increased risk of brain cancer, according to a new World Health Organization-commissioned review of […]
September 3, 2024
TOPLINE: Olanzapine improves chemotherapy-induced nausea and vomiting and leads to higher complete response rates, reduced need for rescue medications, and improved quality of life in patients […]
August 30, 2024
TOPLINE: Gastrointestinal stromal tumors (GISTs) have increased in incidence over the past two decades, with notable survival disparities among racial and ethnic groups, particularly among Black […]
August 30, 2024
TOPLINE: Adjuvant everolimus does not improve recurrence-free or overall survival in patients with papillary and chromophobe subtypes of non–clear cell renal cell carcinoma (RCC) and is […]